BioInvent International AB (publ) (NASDAQ OMX Stockholm) has completed a private placement of new shares with international institutional investors and qualified investors in Sweden through an accelerated bookbuilding procedure. Carnegie Investment Bank and Kempen & Co acted as Joint Global Co-ordinators and Joint Bookrunners.
Vinge and Latham & Watkins were legal advisors to the bookrunners. The Vinge team was headed by capital markets partner Erik Sjöman.
